You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
This is the first update to the guidelines since 2010, and the agency specifically calls out two of the three FDA-cleared Trichomonas NAATs.
The number of decliners in the GenomeWeb Index in April outpaced the gainers 24 to seven amid softness in the broader biotech market.
The presentations were part of a Quidel-sponsored workshop and poster sessions at the Clinical Virology Symposium in Daytona Beach, Fla.
New product revenues more than doubled year over year, while infectious disease test revenues grew 35 percent.
The trichomonas assay is Quidel's sixth assay running on the AmpliVue handheld molecular diagnostic device that has been cleared by the FDA.
Roche's investment in Foundation of up to $1.2B sent Foundation's stock soaring. Otherwise, firms in the GenomeWeb Index saw a mixed month.
The company expects revenues in the range of $63 million to $64 million for the fourth quarter and $182 million to $183 million for full-year 2014.
Trends included expanding test menus and a possible tipping point for point-of-care.
The clearance is the fourth for a Quidel test on the AmpliVue handheld MDx format.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.